Pulmonary dispersion formulations: The impact of dispersed powder properties on pressurized metered dose inhaler stability

Drug Development and Industrial Pharmacy

Volumn 39, Issue 3, 2013, Pages 413-424

  O'Donnell, Kevin P ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Atomic force microscopy; Canister; Density; Inhaler; Particle size; Pressurized; Propellant; Stability; Van der Waals

Indexed keywords

CALCITONIN; FORMOTEROL FUMARATE; LACTOSE; MOMETASONE FUROATE; PROPELLANT; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; TRICHLOROFLUOROMETHANE;

AGGLOMERATION; ATOMIC FORCE MICROSCOPY; CANISTER; CONTAINER; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PACKAGING; DRUG STABILITY; FLOCCULATION; METERED DOSE INHALER; MOISTURE; PARTICLE SIZE; PHASE SEPARATION; PHYSICAL CHEMISTRY; POWDER; POWDER INHALER; REVIEW; SALMON; SUSPENSION;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRY POWDER INHALERS; HUMANS; LUNG; METERED DOSE INHALERS; PARTICLE SIZE; POWDERS;

EID: 84873622135     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.664145     Document Type: Review

References (86)

1. Itoh H, Nishino M, Hatabu H. (2004). Architecture of the lung: morphology and function. J Thorac Imaging, 19:221-227.
2. Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov, 6:67-74.
3. Garcia-Contreras L, Smyth HDC. (2005). Liquid-spray or dry powder systems for inhaled delivery of peptide and proteins Am J Drug Deliv 3:29-45.
4. O'Callaghan, C, Wright P. (2001). The Metered-Dose Inhaler. Drug Delivery to the Lung. In: Bisgaard H, O'Callaghan, C, Smalderone, G. ed. New York:Informa Healthcare.
5. Smyth HD. (2003). The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev, 55:807-828.
6. Ball D, Blanchard J, Jacobson-Kram D, McClellan RO, McGovern T, Norwood DL et al. (2007). Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Toxicol Sci, 97:226-236.
7. Dohmeier DM, Norwood DL, Reckzuegel G, Stults CL, Nagao LM. (2009). Use of polymeric materials in orally inhaled and nasal drug products. Med Device Technol, 20:32, 34, 36-32, 34, 38.
8. Pritchard, JN. (2001). The influence of lung deposition on clinical response 1. J Aerosol Med-Deposition Clearance and Effects in the Lung 14: S19-S26.
9. Carvalho TC, Peters JI, Williams RO 3rd. (2011). Influence of particle size on regional lung deposition-what evidence is there Int J Pharm, 406:1-10.
10. Bisgaard, H, Anhoj, J, Wildhaber, JH. (2002). Spacer devices. Lung Biolo Health Dis 162: 389-420.
11. Berry J, Heimbecher S, Hart JL, Sequeira J. (2003). Influence of the metering chamber volume and actuator design on the aerodynamic particle size of a metered dose inhaler. Drug Dev Ind Pharm, 29:865-876.
12. Wilson AF, Mukai DS, Ahdout JJ. (1991). Effect of canister temperature on performance of metered-dose inhalers. Am Rev Respir Dis, 143:1034-1037.
13. Hoye WL, Mogalian EM, Myrdal PB. (2005). Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols. Am J Health Syst Pharm, 62:2271-2277.
14. Soine WH, Blondino FE, Byron PR. (1992). Chemical stability in pressurized inhlaers formulated as solutions. J Biopharmaceut Sci 3:41-47.
15. Tzou TZ, Pachuta RR, Coy RB, Schultz RK. (1997). Drug form selection in albuterol-containing metered-dose inhaler formulations and its impact on chemical and physical stability. J Pharm Sci, 86:1352-1357.
16. Atkins PJ, Crowder TM. (2004). The design and development of inhalation drug delivery systems. In: Hickey AJ, Pharmaceutical inhalation aerosol technology. New York:Marcel Dekker, 279-310.
17. U.N. (1989). Montreal Protocol on Substances that Deplete the Ozone Layer. New York:Liaison Office of the United Nations Environmental Program.
18. Purewal TS. Greenleaf DJ. (1990). Medicinal aerosol formulations. E. P. 0372777.
19. Byron PR, Miller NC, Blondino FE, Visisch JE, Ward GH. (1994). Some aspects of alternative propellant solvency. In: Byron PR, Dalby RN, Farr SJ. ed. Respiratory Drug Delivery IV. Buffalo Grove:Interpharm Press, 231-242.
20. McDonald KJ, Martin GP. (2000). Transition to CFC-free metered dose inhalers-into the new millennium. Int J Pharm, 201:89-107.
21. Wu L, da Rocha SR. (2007). Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. Langmuir, 23:12104-12110.
22. Wu L, Peguin RPS, Selvam P, Chokshi U, da Rocha, SRP. (2007). Molecular scale behavior in alternative propellant-based inhaler formulations. Lung Biol Health Dis 221:373-398.
23. Blondino FE, Byron PR. (1998). Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants. Drug Dev Ind Pharm, 24:935-945.
24. Williams, RO, III, Hu, C. (2000). Investigation of moisture scavengers in pressurized metered-dose inhalers. S.T.P. Pharma Sciences 10:243-250.
25. Williams RO 3rd, Hu C. (2000). Moisture uptake and its influence on pressurized metered-dose inhalers. Pharm Dev Technol, 5:153-162.
26. Vervaet C, Byron PR. (1999). Drug-surfactant-propellant interations in HFA-formulations. Int J Pharma, 186: 13-30.
27. Gonda, I. (1985). Development of a systematic theory of suspension inhalation aerosols. I. A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles. Int J Pharmaceut 27: 99-116.
28. Purewal, TS., Grant, DJW. (1998). Metered dose inhaler technology. Buffalo Grove:Interpharm Press.
29. Yang W, Peters JI, Williams RO 3rd. (2008). Inhaled nanoparticles-a current review. Int J Pharm, 356:239-247.
30. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796.
31. Yang, B. (2008). Thermal conductivity equations based on Brownian motion in suspensions of nanoparticles (Nanofluids). J Heat Transfer 130.
32. Yang W, Peters JI, Williams RO 3rd. (2008). Inhaled nanoparticles-a current review. Int J Pharm, 356:239-247.
33. Matthews BA, Rhodes CT. (1970). The use of a comparative analysis of sedimentation and Brownian motion as a guide to suspension formulation. Pharm Acta Helv, 45:52-59.
34. Williams, R, Shaw, DJ, Biggs, S. (2007). Introduction to Colloid and Surface Chemistry. London:Butterworth-Heinemann.
35. Michael Y, Snowden MJ, Chowdhry BZ, Ashurst IC, Davies-Cutting CJ, Riley T. (2001). Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. Int J Pharm, 221:165-174.
36. Hickey AJ, Concessio NM. (1994). Flow properties of selected pharmaceutical powders from a vibrating spatula. Part Part Sys Characterization 11:457-462.
37. Lee RW, McShane J, Shaw JM, Wood RW, Shenoy DB. (2008). Particle size reduction. In: R., Liu, ed. Water-insoluble drug formulation. Boca Raton:CRC Press: 467-498.
38. Nyambura BK, Kellaway IW, Taylor KM. (2009). Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers. Int J Pharm, 375:114-122.
39. Bailey MM, Berkland CJ. (2009). Nanoparticle formulations in pulmonary drug delivery. Med Res Rev, 29:196-212.
40. Berry J, Kline LC, Sherwood JK, Chaudhry S, Obenauer-Kutner L, Hart JL et al. (2004). Influence of the size of micronized active pharmaceutical ingredient on the aerodynamic particle size and stability of a metered dose inhaler. Drug Dev Ind Pharm, 30:705-714.
41. Junghanns JAH, Mueller RH. (2008). Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 3: 295-309.
42. Nichols G, Byard S, Bloxham MJ, Botterill J, Dawson NJ, Dennis A et al. (2002). A review of the terms agglomerate and aggregate with a recommendation for nomenclature used in powder and particle characterization. J Pharm Sci, 91:2103-2109.
43. Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113-120.
44. Lei M, Juan W, Zuqing B, Jun Z. (1999). Kinetics of crystal growth of BDP and its solvates in trichlorofluoromethane and their influence on the performance of metered dose inhalers. J Chin Pharmaceut Sci 8:142-147.
45. Phillips EM, Byron PR, Dalby RN. (1993). Axial ratio measurements for early detection of crystal growth in suspension-type metered dose inhalers. Pharm Res, 10:454-456.
46. Williams RO 3rd, Brown J, Liu J. (1999). Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm Dev Technol, 4:167-179.
47. Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U. (2007). Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir, 23:9866-9874.
48. Rogueda P. (2005). Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin Drug Deliv, 2:625-638.
49. Phillips EM. (1992). Crystal growth-formulation dependence and early detection. J Biopharmaceut Sci 3:11-18.
50. Newell HE, Buckton G, Butler DA, Thielmann F, Williams DR. (2001). The use of inverse phase gas chromatography to measure the surface energy of crystalline, amorphous, and recently milled lactose. Pharm Res, 18:662-666.
51. Ranucci JA, Dixit S, Bray RN, Goldman D. (1990). Controlled flocculation in metered-dose aerosol suspensions. Pharmaceut Technol 14:68-74.
52. Young PM, Adi H, Patel T, Law K, Rogueda P, Traini D. (2009). The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. Aerosol Sci 40:324-337.
53. James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ. (2008). The surface characterisation and comparison of two potential submicron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. Int J Pharm, 361:209-221.
54. Tzou T-Z. (1998). Density, excess molar volume, and vapor pressure of propellant mixtures in metered-dose inhalers: deviation from ideal mixtures. Respiratory Drug Delivery VI: Biological, pharmaceutical, clinical and regulatory issues relating to optimized drug delivery by aerosol, the International Symposium, Hilton Head, S.C.
55. Williams RO 3rd, Repka M, Liu J. (1998). Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Drug Dev Ind Pharm, 24:763-770.
56. Robins E, Williams G, Priolkar S. (2007). Development of a pMDI formulation containing salbutamol. Indian J Pharmaceut Sci 69: 724-726.
57. Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA et al. (2002). In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res, 19:258-264.
58. Weers J. (2000). Dispersible powders for inhalation applications. Innovat Pharmaceut Technol 1:111-116.
59. Edwards DA, Ben-Jebria A, Langer R. (1998). Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol, 85:379-385.
60. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML et al. (2000). Hollow porous particles in metered dose inhalers. Pharm Res, 17:168-174.
61. Rosenholm JB, Peiponen KE, Gornov E. (2008). Materials cohesion and interaction forces. Adv Colloid Interface Sci, 141:48-65.
62. Tadmor R. (2001). The London-van der Waals interaction energy between objects of various geometries. J Physics: Condensed Matter 13:L195-L202.
63. Tang P, Greenwood J, Raper JA. (2002). A model to describe the settling behavior of fractal aggregates. J Colloid Interface Sci, 247:210-219.
64. Fargues C, Turchiuli C. (2003). Structural characterization of flocs in relation to their settling performances. Trans IChemE 81(Part A):1171-1178.
65. Zhanpeng J, Yuntao G. (2006). Flocculation morphology: effect of particulate shape and coagulant species on flocculation. Water Sci Technol, 53:9-16.
66. Philipse AP. (1996). The random contact equation and its implications for (colloidal) rods in packings, suspensions, and anisotropic powders. Langmuir 12: 1127-1133.
67. Engstrom JD, Tam JM, Miller MA, Williams RO 3rd, Johnston KP. (2009). Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm Res, 26:101-117.
68. Tam JM, Engstrom JD, Ferrer D, Williams RO 3rd, Johnston KP. (2010). Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers. J Pharm Sci, 99:3150-3165.
69. Reist PC. (1993). Aerosol science and technology, New York, NY: McGraw-Hill.
70. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML et al. (1997). Large porous particles for pulmonary drug delivery. Science, 276:1868-1871.
71. Musante CJ, Schroeter JD, Rosati JA, Crowder TM, Hickey AJ, Martonen TB. (2002). Factors affecting the deposition of inhaled porous drug particles. J Pharm Sci, 91:1590-1600.
72. Cummings, RH. (1999). Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. J Allergy and Clin Immunol, 104:s230-s235.
73. Sherwood JK, Alex S, Salama G, Obenauer-Kutner L, Huyck S, Berry J et al. (2007). Particle size coarsening induced by valve silicone in a metered dose inhaler. Drug Dev Ind Pharm, 33:155-162.
74. Parsons GE, Buckton G, Chatham SM. (1992). The use of surface energy and polarity determinations to predict physical stability of non-polar, non-aqueous suspensions. Int J Pharmaceut 83:163-170.
75. Buckton G, Choularton A, Beezer AE, Chatham SM. (1988). The effect of the comminution technique on the surface energy of a powder. Int J Pharmaceut 47: 121-128.
76. Traini D, Rogueda P, Young P, Price R. (2005). Surface energy and interparticle forces correlations in model pMDI formulations. Pharm Res, 22:816-825.
77. Traini D, Young PM, Rogueda P, Price R (2006). The use of AFM and surface energy measurements to investigate drug-canister material interactions in a model pressurized metered dose inhaler formulation. Aerosol Sci Technol 40:227-236.
78. Traini D, Young PM, Rogueda P, Price R. (2007). In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers. Pharm Res, 24:125-135.
79. Ashayer R, Luckham PF, Manimaaran S, Rogueda P. (2004). Investigation of the molecular interactions in a pMDI formulation by atomic force microscopy. Eur J Pharm Sci, 21:533-543.
80. Young PM, Price R, Lewis D, Edge S, Traini D. (2003). Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. J Colloid Interface Sci, 262:298-302.
81. Hooton JC, German CS, Allen S, Davies MC, Roberts CJ, Tendler SJ et al. (2003). Characterization of particle-interactions by atomic force microscopy: effect of contact area. Pharm Res, 20:508-514.
82. Peguin RP, da Rocha SR. (2008). Solvent-solute interactions in hydrofluoroalkane propellants. J Phys Chem B, 112:8084-8094.
83. Wu L, Al-Haydari M, da Rocha SR. (2008). Novel propellantdriven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes. Eur J Pharm Sci, 33:146-158.
84. Wu L, Bharatwaj B, Panyam J, da Rocha SR. (2008). Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm Res, 25:289-301.
85. Li HY, Seville PC. (2010). Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm, 385:73-78.
86. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. (2004). Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res, 21:1607-1614.